Arpeggio

Curated by Signal

Provider of drug discovery platform for the treatment of cancer

Overview

Provider of drug discovery platform for the treatment of cancer. The company uses DNA sequencing and CRISPR-based screening technology to identify therapeutic targets and biomarkers to treat cancer. The company is developing drug candidates for Sarcomas, Lung Adenocarcinoma, and autoimmune diseases.

Key facts

Founded: 2017
Headquarters: Boulder, United States
Stage: Sign up to view
Industry: Life Sciences Technology

Contact

Email: Sign up to view

More on Vanberra Signal

Members only

Business overviewCore metrics and financials PeopleLeadership and key people Similar companiesPeers and competitors Deep AnalysisAI-generated strategic report

Competitors & similar companies

More Life Sciences Technology companies

Civitas Therapeutics
Pulmonary delivery therapies for relief from intermittent debilitating motor fluctuations
Life Sciences TechnologyChelsea, United States
Nexilico
Developer of computational tools for microbiome analytics
Life Sciences TechnologyBerkeley, United States
Nimbus Therapeutics
Developer of targeted therapeutics for cancer, metabolic and inflammatory diseases
Life Sciences TechnologyCambridge, United States

About Arpeggio

What does Arpeggio do?

Provider of drug discovery platform for the treatment of cancer.

Where is Arpeggio headquartered?

Arpeggio is headquartered in Boulder, United States.

When was Arpeggio founded?

Arpeggio was founded in 2017.

Which sector is Arpeggio in?

Arpeggio operates in Life Sciences Technology.

Who are Arpeggio's competitors?

Companies similar to Arpeggio include Civitas Therapeutics, Nexilico, and Nimbus Therapeutics.